Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Immunotherapy Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab in Patients with Advanced Solid Malignancies

NCT06782555 is registered in ClinicalTrials.gov with ImmunoGenesis as lead sponsor.

NCT NCT06782555
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06782555 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Immunotherapy Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab in Patients with Advanced Solid Malignancies
Lead sponsor
ImmunoGenesis
Phase
Phase 1/2
Overall status
Recruiting
Start date
January 8, 2025
Completion date
January 31, 2028
Enrollment
71 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic head and neck squamous cell carcinoma, metastatic pancreatic cancer, metastatic prostate cancer